Needham & Company Maintains a 'Hold' on Obagi Medical Products (OMPI); Strong Start, But Valuation Keeps Us Sidelined

May 4, 2012 9:28 AM EDT
Get Alerts OMPI Hot Sheet
Price: $23.98 --0%

Rating Summary:
    0 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 9
Trade OMPI Now!
Join SI Premium – FREE
Needham & Company maintains a 'Hold' on Obagi Medical Products (NASDAQ: OMPI).

Analyst, Elliot Wilbur, said, "OMPI kicked off its 2012 financials with the largest positive revenue surprise vs. consensus in over two years, even more impressive considering the company derived essentially no benefit from new physician account additions and only a modest contribution from new product introductions in the period. Despite the strong start, management stuck to its guns, reiterating prior year revenue guidance though with resumption of shipments into the Texas market (~8% of historical sales) just yesterday, we suspect top-line trends will at least track toward the higher end of current guidance range."

For an analyst ratings summary and ratings history on Obagi Medical Products click here. For more ratings news on Obagi Medical Products click here.

Shares of Obagi Medical Products closed at $12.85 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Needham & Company

Add Your Comment